Retrieve available abstracts of 47 articles: HTML format
Single Articles
June 2025
LI Y, Zheng X, Xie L, Kapustina M, et al Heat shock protein 90 chaperone activity is required for hepatitis A virus
replication.
J Virol. 2025 Jun 5:e0050225. doi: 10.1128/jvi.00502. PubMedAbstract available
April 2025
WU S, Chen Z, Zhang Z, Xu J, et al Ubiquitin-dependent proteasomal degradation of small hepatitis B virus surface
antigen mediated by TRIM21 and antagonized by OTUD4.
J Virol. 2025 Apr 25:e0230924. doi: 10.1128/jvi.02309. PubMedAbstract available
YAN H, Peng B, He W, Zhong G, et al Correction for Yan et al., "Molecular Determinants of Hepatitis B and D Virus
Entry Restriction in Mouse Sodium Taurocholate Cotransporting Polypeptide".
J Virol. 2025 Apr 16:e0044525. doi: 10.1128/jvi.00445. PubMed
March 2025
CHEN F, Wettengel JM, Gegenfurtner F, Moosmuller J, et al Identification of NTCP animal orthologs supporting hepatitis B virus binding and
infection.
J Virol. 2025 Mar 5:e0183324. doi: 10.1128/jvi.01833. PubMedAbstract available
January 2025
NOGALES A, Alonso C, Moreno S, Lorenzo G, et al Novel replication-competent reporter-expressing Rift Valley fever viruses for
molecular studies.
J Virol. 2025;99:e0178224. PubMedAbstract available
YAN H, Liu C, Li Y, Tang S, et al The characterization and structural basis of a human broadly binding antibody to
HBV core protein.
J Virol. 2025;99:e0169424. PubMedAbstract available
CHEN Z, Eggerman TL, Bocharov AV, Baranova IN, et al APOBEC-1 cofactors regulate APOBEC3-induced mutations in hepatitis B virus.
J Virol. 2025 Jan 27:e0187924. doi: 10.1128/jvi.01879. PubMedAbstract available
HUANG H-E, Colasanti O, Li T-F, Lohmann V, et al Limited impact of hepatitis A virus 3C protease-mediated cleavage on the
functions of NEMO in human hepatocytes.
J Virol. 2025 Jan 24:e0226424. doi: 10.1128/jvi.02264. PubMedAbstract available
FEDORCHENKO SV, Klimenko Z, Martynovich T, Solianyk I, et al Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who
previously failed a regimen containing second-generation NS5A inhibitors with
sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.
J Virol. 2025 Jan 22:e0184324. doi: 10.1128/jvi.01843. PubMedAbstract available
November 2024
STEIGMANN JC, Zhou X, Suttenberg LN, Salman I, et al Effects of immunoproteasome inhibition on acute respiratory infection with murine
hepatitis virus strain 1.
J Virol. 2024 Nov 7:e0123824. doi: 10.1128/jvi.01238. PubMedAbstract available
KANG N, Liu N, Liu M, Zhang S, et al Identification and characterization of host factor VCPIP1 as a multi-functional
positive regulator of hepatitis B virus.
J Virol. 2024 Nov 4:e0158124. doi: 10.1128/jvi.01581. PubMedAbstract available
October 2024
WU Y, Ren L, Mao C, Shen Z, et al Small hepatitis B virus surface antigen (SHBs) induces dyslipidemia by
suppressing apolipoprotein-AII expression through ER stress-mediated modulation
of HNF4alpha and C/EBPgamma.
J Virol. 2024 Oct 29:e0123924. doi: 10.1128/jvi.01239. PubMedAbstract available
QUELLEC J, Piro-Megy C, Cannac M, Nisole S, et al Rift Valley fever virus is able to cross the human blood-brain barrier in vitro
by direct infection with no deleterious effects.
J Virol. 2024;98:e0126724. PubMedAbstract available
MATRENEC R, Oropeza CE, Dekoven E, Matrenec C, et al Foxa deficiency restricts hepatitis B virus biosynthesis through epigenic
silencing.
J Virol. 2024 Oct 8:e0137124. doi: 10.1128/jvi.01371. PubMedAbstract available
LI A, Zhao K, Duan Y, Zhang B, et al SARS-CoV-2 nsp13 suppresses hepatitis B virus replication by targeting cccDNA
transcription.
J Virol. 2024 Oct 7:e0104224. doi: 10.1128/jvi.01042. PubMedAbstract available
September 2024
IBRAHIM MK, Liu C-D, Zhang L, Yu X, et al The loss of hepatitis B virus receptor NTCP/SLC10A1 in human liver cancer cells
is due to epigenetic silencing.
J Virol. 2024 Sep 19:e0118724. doi: 10.1128/jvi.01187. PubMedAbstract available
August 2024
LOWERY SA, Schuster N, Wong L-YR, Carrillo T Jr, et al Mouse hepatitis virus JHMV I protein is required for maximal virulence.
J Virol. 2024 Aug 19:e0068024. doi: 10.1128/jvi.00680. PubMedAbstract available
July 2024
ZHANG J, Wang Q, Yuan W, Li J, et al Both middle and large envelope proteins can mediate neutralization of hepatitis B
virus infectivity by anti-preS2 antibodies: escape by naturally occurring preS2
deletions.
J Virol. 2024 Jul 30:e0192923. doi: 10.1128/jvi.01929. PubMedAbstract available
MCMILLEN CM, Megli C, Radisic R, Skvarca LB, et al Vaccine strains of Rift Valley fever virus exhibit attenuation at the
maternal-fetal placental interface.
J Virol. 2024 Jul 17:e0098324. doi: 10.1128/jvi.00983. PubMedAbstract available
June 2024
HE Q, Liu T, Yang X, Yuan D, et al Optimization of immunosuppression strategies for the establishment of chronic
hepatitis E virus infection in rabbits.
J Virol. 2024 Jun 20:e0084624. doi: 10.1128/jvi.00846. PubMedAbstract available
LIU J, Ito M, Liu L, Nakashima K, et al Involvement of ribosomal protein L17 and Y-box binding protein 1 in the assembly
of hepatitis C virus potentially via their interaction with the 3' untranslated
region of the viral genome.
J Virol. 2024 Jun 20:e0052224. doi: 10.1128/jvi.00522. PubMedAbstract available
WOYTINEK K, Glitscher M, Hildt E Antagonism of epidermal growth factor receptor signaling favors hepatitis E virus
life cycle.
J Virol. 2024 Jun 10:e0058024. doi: 10.1128/jvi.00580. PubMedAbstract available
May 2024
WON J, Kang HS, Kim NY, Dezhbord M, et al Tripartite motif-containing protein 21 is involved in IFN-gamma-induced suppression
of hepatitis B virus by regulating hepatocyte nuclear factors.
J Virol. 2024 May 23:e0046824. doi: 10.1128/jvi.00468. PubMedAbstract available
PARONETTO O, Allioux C, Dimeglio C, Lobjois L, et al Characterization of virus?host recombinant variants of the hepatitis E virus.
J Virol. 2024 May 7:e0029524. doi: 10.1128/jvi.00295. PubMedAbstract available
April 2024
SCHOLLMEIER A, Basic M, Glitscher M, Hildt E, et al The impact of HBx protein on mitochondrial dynamics and associated signaling
pathways strongly depends on the hepatitis B virus genotype.
J Virol. 2024 Apr 17:e0042424. doi: 10.1128/jvi.00424. PubMedAbstract available
March 2024
SHENG Y, Deng Y, Li X, Ji P, et al Hepatitis E virus ORF3 protein hijacking thioredoxin domain-containing protein 5
(TXNDC5) for its stability to promote viral particle release.
J Virol. 2024 Mar 29:e0164923. doi: 10.1128/jvi.01649. PubMedAbstract available
MCCOULLOUGH LC, Sadauskas T, Sozzi V, Mak KY, et al The in vitro replication phenotype of hepatitis B virus (HBV) splice variants Sp3
and Sp9 and their impact on wild-type HBV replication.
J Virol. 2024 Mar 19:e0153823. doi: 10.1128/jvi.01538. PubMedAbstract available
LI Y, Lemon SM Biochemical analysis of the host factor activity of ZCCHC14 in hepatitis A virus
replication.
J Virol. 2024 Mar 19:e0005724. doi: 10.1128/jvi.00057. PubMedAbstract available
TAMURA T, Yamamoto H, Ogino S, Morioka Y, et al A rapid and versatile reverse genetics approach for generating recombinant
positive-strand RNA viruses that use IRES-mediated translation.
J Virol. 2024;98:e0163823. PubMedAbstract available
BERKE JM, Tan Y, Sauviller S, Wu D-t, et al Class A capsid assembly modulator apoptotic elimination of hepatocytes with high
HBV core antigen level in vivo is dependent on de novo core protein translation.
J Virol. 2024;98:e0150223. PubMedAbstract available
February 2024
FRERICKS N, Brown RJP, Reinecke BM, Herrmann M, et al Unraveling the dynamics of hepatitis C virus adaptive mutations and their impact
on antiviral responses in primary human hepatocytes.
J Virol. 2024 Feb 6:e0192123. doi: 10.1128/jvi.01921. PubMedAbstract available
NAKAJIMA S, Watashi K, Kato T, Muramatsu M, et al Correction for Nakajima et al., "Biochemical and Structural Properties of
Entecavir-Resistant Hepatitis B Virus Polymerase with L180M/M204V Mutations".
J Virol. 2024 Feb 2:e0182323. doi: 10.1128/jvi.01823. PubMed
January 2024
SHEN Z, Zhang S, Gao Z, Yu X, et al Intrahepatic homeobox protein MSX-1 is a novel host restriction factor of
hepatitis B virus.
J Virol. 2024 Jan 16:e0134523. doi: 10.1128/jvi.01345. PubMedAbstract available
MATRENEC R, Oropeza CE, Dekoven E, Tarnow G, et al Ten-eleven translocation (Tet) methylcytosine dioxygenase-dependent viral DNA
demethylation mediates in vivo hepatitis B virus (HBV) biosynthesis.
J Virol. 2024 Jan 5:e0172123. doi: 10.1128/jvi.01721. PubMedAbstract available
CASIANO MATOS J, Harichandran K, Tang J, Sviridov DO, et al Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and
evade antibody recognition.
J Virol. 2024 Jan 4:e0084923. doi: 10.1128/jvi.00849. PubMedAbstract available
December 2023
HAGA Y, Meyer K, Sung MMH, Reagan EK, et al Hepatitis C virus modified sE2(F442NYT) as an antigen in candidate vaccine
facilitates human immune cell activation.
J Virol. 2023 Dec 12:e0180923. doi: 10.1128/jvi.01809. PubMedAbstract available
GOBRAN ST, Pagliuzza A, Khedr O, Fert A, et al DAA-mediated HCV cure reduces HIV DNA levels in HCV/HIV coinfected people.
J Virol. 2023 Dec 5:e0110523. doi: 10.1128/jvi.01105. PubMedAbstract available
November 2023
BAJPAI PS, Collignon L, Solund C, Madsen LW, et al Full-length sequence analysis of hepatitis C virus genotype 3b strains and
development of an in vivo infectious 3b cDNA clone.
J Virol. 2023 Nov 21:e0092523. doi: 10.1128/jvi.00925. PubMedAbstract available
XU X, Zhang L, Ye G, Shi J, et al Hepatitis B doubly spliced protein (HBDSP) promotes hepatocellular carcinoma cell
apoptosis via ETS1/GATA2/YY1-mediated p53 transcription.
J Virol. 2023 Nov 6:e0108723. doi: 10.1128/jvi.01087. PubMedAbstract available
October 2023
SEEGER C A CRISPR-based system to investigate HBV cccDNA biology.
J Virol. 2023;97:e0118523. PubMedAbstract available
VANRUSSELT H, Kum DB, Taverniti V, Liu C, et al Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and
in vivo profiles.
J Virol. 2023;97:e0072223. PubMedAbstract available
ARIFFIANTO A, Deng L, Abe T, Matsui C, et al Oxidative stress sensor Keap1 recognizes HBx protein to activate the Nrf2/ARE
signaling pathway, thereby inhibiting hepatitis B virus replication.
J Virol. 2023 Oct 6:e0128723. doi: 10.1128/jvi.01287. PubMedAbstract available
LI Y, Yang Y, Li T, Wang Z, et al Activation of AIM2 by hepatitis B virus results in antiviral immunity that
suppresses hepatitis C virus during coinfection.
J Virol. 2023 Oct 3:e0109023. doi: 10.1128/jvi.01090. PubMedAbstract available
September 2023
NEPAL S, Holmstrom ED Single-molecule-binding studies of antivirals targeting the hepatitis C virus
core protein.
J Virol. 2023 Sep 29:e0089223. doi: 10.1128/jvi.00892. PubMedAbstract available
XU L, Paine AC, Barbeau DJ, Alencastro F, et al Limiting viral replication in hepatocytes alters Rift Valley fever virus disease
manifestations.
J Virol. 2023;97:e0085323. PubMedAbstract available
SHEN S, Liu W, Zeng G, Liang H, et al Conditional replication and secretion of hepatitis B virus genome uncover the
truncated 3' terminus of encapsidated viral pregenomic RNA.
J Virol. 2023 Sep 27:e0076023. doi: 10.1128/jvi.00760. PubMedAbstract available
NAGASHIMA S, Primadharsini PP, Nishiyama T, Takahashi M, et al Development of a HiBiT-tagged reporter hepatitis E virus and its utility as an
antiviral drug screening platform.
J Virol. 2023 Sep 8:e0050823. doi: 10.1128/jvi.00508. PubMedAbstract available